CMS is initiating a National Coverage Analysis for CAR-T therapies

In 2017, the Food and Drug Administration approved the first chimeric antigen receptor (CAR)-T cell therapies, now the Centers for Medicare and Medicaid (CMS) have initiated a National Coverage Analysis for CAR-T therapies in order to determine whether the pricey cancer drugs will be nationally reimbursed by Medicare. Although CMS previously disclosed that it had agreed to reimburse hospitals through the Medicare Part B program, the National Coverage Analysis is the first step in developing a uniform coverage policy for the nation. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.